On May 23, 2025, analyst Serge Belanger from Needham provided an updated analysis on Arcutis Biotherapeutics (ARQT, Financial), reiterating a 'Buy' rating for the stock. The current price target is maintained at $20.00 USD, consistent with previous assessments.
Arcutis Biotherapeutics (ARQT, Financial) continues to hold favorable prospects according to Needham's analysis, with no change in the price target from the prior $20.00 USD. The decision to maintain the 'Buy' rating underscores the analyst's confidence in the stock's potential performance.
Investors in Arcutis Biotherapeutics (ARQT, Financial) can view this reiterated 'Buy' rating and stable price target as an indication of the firm's steady outlook. The analysis suggests that the company is on track with Needham's expectations, making it an attractive option for investors seeking opportunities in the biotech sector.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 6 analysts, the average target price for Arcutis Biotherapeutics Inc (ARQT, Financial) is $21.50 with a high estimate of $29.00 and a low estimate of $19.00. The average target implies an upside of 57.39% from the current price of $13.66. More detailed estimate data can be found on the Arcutis Biotherapeutics Inc (ARQT) Forecast page.
Based on the consensus recommendation from 7 brokerage firms, Arcutis Biotherapeutics Inc's (ARQT, Financial) average brokerage recommendation is currently 1.7, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
